BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines presented data at ESMO 2026 on three investigational cancer treatments. GPC3 x 4-1BB bispecific showed 36% ORR in liver cancer, PRMT5 inhibitor demonstrated 25.3% ORR in lung cancer, and CEA-targeting ADC achieved 56% ORR in high-CEA lung cancer. The company plans global trials for these treatments.
How this was made
The 30-second read
Why it matters
The data provide the first public efficacy readouts, earning Fast Track and Orphan designations, and set the stage for upcoming registrational trials.
Market read
First‑time disclosure of promising oncology data for a US‑listed biotech, likely to move the stock and influence sector sentiment.
What to watch
The small patient numbers and early‑stage nature of the trials mean efficacy and safety remain uncertain; competition in HCC and NSCLC is intense.
Background
BeOne Medicines presented multiple investigational oncology assets at ESMO 2026, including a bispecific antibody for HCC, a brain‑penetrant PRMT5 inhibitor for MTAP‑deficient NSCLC, and a CEA‑targeting ADC for CEA‑high NSCLC.
Ticker impact
BeOne Medicines disclosed Phase 1 and Phase 3 trial data showing 36% ORR in HCC and promising results in NSCLC, marking the first public release of these results.
likely upside as the data exceeds typical late‑line HCC benchmarks and earns Fast Track designation.
The disclosed response rates and Fast Track/Orphan designations are new, material information for a biotech with a US listing, prompting immediate market reaction.
Market effects
Strengthens the oncology biotech sector, especially firms developing bispecific antibodies and PRMT5 inhibitors.
May boost US biotech indices and Canadian biotech exposure where BeOne has operations.
Highlights continued pipeline momentum for global cancer therapeutics, potentially influencing cross‑border investors.
Counterpoint
If the data does not translate into regulatory approval or commercial partnerships, the hype could fade and the stock may correct.
Key entities
- companyBeOne Medicines Ltd.
Global oncology biotech (Nasdaq: ONC) reporting trial data.
- drug_candidateBGB-B2033
GPC3×4‑1BB bispecific antibody for hepatocellular carcinoma.
- drug_candidateBGB-58067
Brain‑penetrant PRMT5 inhibitor for MTAP‑deficient NSCLC.
- drug_candidateBG-C477
CEA‑targeting ADC for CEA‑high NSCLC.
